We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
(-11%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
9.21%
Top 10 Holdings %
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$38.8M |
| 2 |
Biogen
BIIB
|
+$26M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$23.3M |
| 4 |
Viatris
VTRS
|
+$21M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$16.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$28.9M |
| 2 |
Merck
MRK
|
+$17.9M |
| 3 |
ExxonMobil
XOM
|
+$14.8M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$13.4M |
| 5 |
Lipocine
LPCN
|
+$7.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.86% |
| 2 | Healthcare | 14.52% |
| 3 | Energy | 1.33% |
| 4 | Technology | 0.46% |
| 5 | Materials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Viatris
VTRS
$19B
| $15.2M | 0.63% |
+376,827
| New | +$21M |
|
|
PXD
27
DELISTED
Pioneer Natural Resource Co.
PXD
| $15M | 0.62% |
123,600
+47,327
| +62% | +$5.9M |
|
|
PXD
28
PUT
DELISTED
Pioneer Natural Resource Co.
PXD
| $15M | 0.62% |
1,236
| – | – |
|
|
GBT
29
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14.5M | 0.6% |
+342,857
| New | +$16.2M |
|
30
CALL
Alnylam Pharmaceuticals
ALNY
$32.4B
| $13.5M | 0.55% |
1,676
-2,481
| -60% | -$276K |
|
|
LUMO
31
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $13.3M | 0.55% |
411
+64
| +18% | +$28.1K |
|
32
PUT
AbbVie
ABBV
$466B
| $12.4M | 0.51% |
2,272
-1,432
| -39% | -$93.2K |
|
33
CALL
Apple
AAPL
$4.81T
| $12.2M | 0.5% |
+4,440
| New | +$130K |
|
34
CALL
United Therapeutics
UTHR
$21.6B
| $12M | 0.5% |
918
+382
| +71% | +$61.3K |
|
|
IOC
35
PUT
DELISTED
Interoil Corporation
IOC
| $11.3M | 0.47% |
3,356
| – | – |
|
|
IOC
36
DELISTED
Interoil Corporation
IOC
| $11.1M | 0.46% |
328,705
+175,561
| +115% | +$7.1M |
|
37
Edwards Lifesciences
EW
$49.5B
| $11M | 0.45% |
463,530
+356,640
| +334% | +$8.61M |
|
38
PUT
Tenet Healthcare
THC
$21B
| $10.7M | 0.44% |
2,907
-3,241
| -53% | -$167K |
|
|
MBLY
39
DELISTED
Mobileye N.V.
MBLY
| $10.7M | 0.44% |
235,819
+161,987
| +219% | +$8.9M |
|
40
CALL
Heron Therapeutics
HRTX
$59.3M
| $10.3M | 0.42% |
4,223
+938
| +29% | +$31.3K |
|
|
CEMP
41
CALL
DELISTED
Cempra, Inc.
CEMP
| $10.2M | 0.42% |
3,649
+3,148
| +628% | +$117K |
|
|
KITE
42
PUT
DELISTED
Kite Pharma, Inc.
KITE
| $10.2M | 0.42% |
1,823
+1,721
| +1,687% | +$108K |
|
43
CALL
MannKind Corp
MNKD
$1.16B
| $9.93M | 0.41% |
6,186
+2,895
| +88% | +$61.5K |
|
44
Gevo
GEVO
$388M
| $9.82M | 0.4% |
250
-188
| -43% | -$175K |
|
|
45
Tenet Healthcare
THC
$21B
| $9.08M | 0.37% |
+245,938
| New | +$12.7M |
|
46
PUT
Agios Pharmaceuticals
AGIO
$1.99B
| $8.28M | 0.34% |
1,173
+837
| +249% | +$81.8K |
|
|
RGLS
47
CALL
DELISTED
Regulus Therapeutics
RGLS
| $7.93M | 0.33% |
101
+3
| +3% | +$3.08K |
|
48
Tenax Therapeutics
TENX
$68.5M
| $7.89M | 0.33% |
81
-3
| -4% | -$343K |
|
|
49
Agios Pharmaceuticals
AGIO
$1.99B
| $7.73M | 0.32% |
+109,521
| New | +$10.7M |
|
|
ALXN
50
DELISTED
Alexion Pharmaceuticals
ALXN
| $7.72M | 0.32% |
49,397
+33,502
| +211% | +$6.11M |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q3 2015 Portfolio in Review
As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.
- Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
- Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
- Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
- Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
- Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
- Sabby Management opened 130 new positions and closed 66 in Q3 2015.
- Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.
Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.